Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis

From medical needs to a new treatment algorithm

Thomas Luger, Linda De Raeve, Carlo Gelmetti, Talia Kakourou, Alexandra Katsarou, Julien Lambert, Marie Anne Morren, Arnold Oranje, Mireille Ruer, Server Serdaroglu, Antonio Torrelo, Thomas Werfel

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Pimecrolimus 1% cream is an effective, non-corticosteroid, topical antiinflammatory treatment for atopic dermatitis (AD). The aim of this article was to review published clinical data that have examined how pimecrolimus can address the medical needs of AD patients. Clinical studies have demonstrated that early treatment with pimecrolimus decreases the progression to disease flares, rapidly improves pruritus and significantly enhances quality of life. Patients find the formulation easy to apply, which may result in improved adherence with the treatment regimen. Pimecrolimus, in contrast to topical corticosteroids (TCSs), does not induce skin atrophy or epidermal barrier dysfunction and is highly effective for the treatment of AD in sensitive skin areas. Furthermore, pimecrolimus reduces the incidence of skin infections compared with TCSs and is not associated with other TCS-related side effects such as striae, telangiectasia and hypothalamic-pituitary-adrenal axis suppression. An additional benefit of pimecrolimus is its substantial steroid sparing effect. On the basis of these data, a new treatment algorithm for patients with mild-to-moderate AD is proposed in which pimecrolimus is recommended as a first line therapy for patients with established mild AD at the first signs and symptoms of disease. Pimecrolimus is also recommended for mild-to-moderate AD after initial treatment with a TCS. After resolution of lesions, maintenance treatment with pimecrolimus may effectively prevent subsequent disease flares. In conclusion, the clinical profile of pimecrolimus suggests that it may be considered the drug of choice for the treatment of mild-tomoderate AD in children as well as adults and particularly in sensitive skin areas.

Original languageEnglish
Pages (from-to)758-766
Number of pages9
JournalEuropean Journal of Dermatology
Volume23
Issue number6
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Atopic Dermatitis
Adrenal Cortex Hormones
Therapeutics
Skin
pimecrolimus
Telangiectasis
Pruritus
Signs and Symptoms
Atrophy
Disease Progression
Anti-Inflammatory Agents
Steroids
Quality of Life
Incidence

Keywords

  • Atopic dermatitis
  • Pimecrolimus
  • Topical calcineurin inhibitor
  • Topical corticosteroid
  • Treatment algorithm

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Cite this

Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis : From medical needs to a new treatment algorithm. / Luger, Thomas; De Raeve, Linda; Gelmetti, Carlo; Kakourou, Talia; Katsarou, Alexandra; Lambert, Julien; Morren, Marie Anne; Oranje, Arnold; Ruer, Mireille; Serdaroglu, Server; Torrelo, Antonio; Werfel, Thomas.

In: European Journal of Dermatology, Vol. 23, No. 6, 11.2013, p. 758-766.

Research output: Contribution to journalArticle

Luger, T, De Raeve, L, Gelmetti, C, Kakourou, T, Katsarou, A, Lambert, J, Morren, MA, Oranje, A, Ruer, M, Serdaroglu, S, Torrelo, A & Werfel, T 2013, 'Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: From medical needs to a new treatment algorithm', European Journal of Dermatology, vol. 23, no. 6, pp. 758-766. https://doi.org/10.1684/ejd.2013.2169
Luger, Thomas ; De Raeve, Linda ; Gelmetti, Carlo ; Kakourou, Talia ; Katsarou, Alexandra ; Lambert, Julien ; Morren, Marie Anne ; Oranje, Arnold ; Ruer, Mireille ; Serdaroglu, Server ; Torrelo, Antonio ; Werfel, Thomas. / Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis : From medical needs to a new treatment algorithm. In: European Journal of Dermatology. 2013 ; Vol. 23, No. 6. pp. 758-766.
@article{2ee7701c2ac64f7891728a8e40669283,
title = "Recommendations for pimecrolimus 1{\%} cream in the treatment of mild-to-moderate atopic dermatitis: From medical needs to a new treatment algorithm",
abstract = "Pimecrolimus 1{\%} cream is an effective, non-corticosteroid, topical antiinflammatory treatment for atopic dermatitis (AD). The aim of this article was to review published clinical data that have examined how pimecrolimus can address the medical needs of AD patients. Clinical studies have demonstrated that early treatment with pimecrolimus decreases the progression to disease flares, rapidly improves pruritus and significantly enhances quality of life. Patients find the formulation easy to apply, which may result in improved adherence with the treatment regimen. Pimecrolimus, in contrast to topical corticosteroids (TCSs), does not induce skin atrophy or epidermal barrier dysfunction and is highly effective for the treatment of AD in sensitive skin areas. Furthermore, pimecrolimus reduces the incidence of skin infections compared with TCSs and is not associated with other TCS-related side effects such as striae, telangiectasia and hypothalamic-pituitary-adrenal axis suppression. An additional benefit of pimecrolimus is its substantial steroid sparing effect. On the basis of these data, a new treatment algorithm for patients with mild-to-moderate AD is proposed in which pimecrolimus is recommended as a first line therapy for patients with established mild AD at the first signs and symptoms of disease. Pimecrolimus is also recommended for mild-to-moderate AD after initial treatment with a TCS. After resolution of lesions, maintenance treatment with pimecrolimus may effectively prevent subsequent disease flares. In conclusion, the clinical profile of pimecrolimus suggests that it may be considered the drug of choice for the treatment of mild-tomoderate AD in children as well as adults and particularly in sensitive skin areas.",
keywords = "Atopic dermatitis, Pimecrolimus, Topical calcineurin inhibitor, Topical corticosteroid, Treatment algorithm",
author = "Thomas Luger and {De Raeve}, Linda and Carlo Gelmetti and Talia Kakourou and Alexandra Katsarou and Julien Lambert and Morren, {Marie Anne} and Arnold Oranje and Mireille Ruer and Server Serdaroglu and Antonio Torrelo and Thomas Werfel",
year = "2013",
month = "11",
doi = "10.1684/ejd.2013.2169",
language = "English",
volume = "23",
pages = "758--766",
journal = "European Journal of Dermatology",
issn = "1167-1122",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis

T2 - From medical needs to a new treatment algorithm

AU - Luger, Thomas

AU - De Raeve, Linda

AU - Gelmetti, Carlo

AU - Kakourou, Talia

AU - Katsarou, Alexandra

AU - Lambert, Julien

AU - Morren, Marie Anne

AU - Oranje, Arnold

AU - Ruer, Mireille

AU - Serdaroglu, Server

AU - Torrelo, Antonio

AU - Werfel, Thomas

PY - 2013/11

Y1 - 2013/11

N2 - Pimecrolimus 1% cream is an effective, non-corticosteroid, topical antiinflammatory treatment for atopic dermatitis (AD). The aim of this article was to review published clinical data that have examined how pimecrolimus can address the medical needs of AD patients. Clinical studies have demonstrated that early treatment with pimecrolimus decreases the progression to disease flares, rapidly improves pruritus and significantly enhances quality of life. Patients find the formulation easy to apply, which may result in improved adherence with the treatment regimen. Pimecrolimus, in contrast to topical corticosteroids (TCSs), does not induce skin atrophy or epidermal barrier dysfunction and is highly effective for the treatment of AD in sensitive skin areas. Furthermore, pimecrolimus reduces the incidence of skin infections compared with TCSs and is not associated with other TCS-related side effects such as striae, telangiectasia and hypothalamic-pituitary-adrenal axis suppression. An additional benefit of pimecrolimus is its substantial steroid sparing effect. On the basis of these data, a new treatment algorithm for patients with mild-to-moderate AD is proposed in which pimecrolimus is recommended as a first line therapy for patients with established mild AD at the first signs and symptoms of disease. Pimecrolimus is also recommended for mild-to-moderate AD after initial treatment with a TCS. After resolution of lesions, maintenance treatment with pimecrolimus may effectively prevent subsequent disease flares. In conclusion, the clinical profile of pimecrolimus suggests that it may be considered the drug of choice for the treatment of mild-tomoderate AD in children as well as adults and particularly in sensitive skin areas.

AB - Pimecrolimus 1% cream is an effective, non-corticosteroid, topical antiinflammatory treatment for atopic dermatitis (AD). The aim of this article was to review published clinical data that have examined how pimecrolimus can address the medical needs of AD patients. Clinical studies have demonstrated that early treatment with pimecrolimus decreases the progression to disease flares, rapidly improves pruritus and significantly enhances quality of life. Patients find the formulation easy to apply, which may result in improved adherence with the treatment regimen. Pimecrolimus, in contrast to topical corticosteroids (TCSs), does not induce skin atrophy or epidermal barrier dysfunction and is highly effective for the treatment of AD in sensitive skin areas. Furthermore, pimecrolimus reduces the incidence of skin infections compared with TCSs and is not associated with other TCS-related side effects such as striae, telangiectasia and hypothalamic-pituitary-adrenal axis suppression. An additional benefit of pimecrolimus is its substantial steroid sparing effect. On the basis of these data, a new treatment algorithm for patients with mild-to-moderate AD is proposed in which pimecrolimus is recommended as a first line therapy for patients with established mild AD at the first signs and symptoms of disease. Pimecrolimus is also recommended for mild-to-moderate AD after initial treatment with a TCS. After resolution of lesions, maintenance treatment with pimecrolimus may effectively prevent subsequent disease flares. In conclusion, the clinical profile of pimecrolimus suggests that it may be considered the drug of choice for the treatment of mild-tomoderate AD in children as well as adults and particularly in sensitive skin areas.

KW - Atopic dermatitis

KW - Pimecrolimus

KW - Topical calcineurin inhibitor

KW - Topical corticosteroid

KW - Treatment algorithm

UR - http://www.scopus.com/inward/record.url?scp=84893217641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893217641&partnerID=8YFLogxK

U2 - 10.1684/ejd.2013.2169

DO - 10.1684/ejd.2013.2169

M3 - Article

VL - 23

SP - 758

EP - 766

JO - European Journal of Dermatology

JF - European Journal of Dermatology

SN - 1167-1122

IS - 6

ER -